The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

被引:0
|
作者
Kerb R. [1 ]
Aynacioglu A.S. [2 ,3 ]
Brockmöller J. [2 ]
Schlagenhaufer R. [1 ]
Bauer S. [2 ]
Szekeres T. [4 ]
Hamwi A. [4 ]
Fritzer-Szekeres M. [4 ]
Baumgartner C. [5 ]
Öngen H.Z. [6 ]
Güzelbey P. [6 ]
Roots I. [2 ]
Brinkmann U. [1 ]
机构
[1] Epidauros Biotechnology AG, Pharmacogenetics Laboratory, Bernried
[2] Institute of Clinical Pharmacology, University Medical Center Charité, Humboldt University, Berlin
[3] Department of Pharmacology, Medical Faculty, Pamukkale University, Denizli
[4] Institute of Clinical Chemistry, AKH-Wien, University of Vienna, Vienna
[5] Institute of Neurology, AKHWien, University of Vienna, Vienna
[6] Department of Pharmacology, University of Gaziantep
关键词
Pharmacogenetlcs; Polymorphism; TDM;
D O I
10.1038/sj.tpj.6500025
中图分类号
学科分类号
摘要
Phenytoin, an anticonvulsant, exhibits nonlinear pharmacokinetics with large interindividual differences. Because of its small therapeutic range with the risk of therapeutic failure or adverse drug effects in susceptible persons, therapeutic drug monitoring is frequently applied. The interindividual differences in dose response can partially be explained by known genetic polymorphisms in the metabolic enzyme CYP2C9 but a large deal of individual variability remains still unexplained. Part of this variability might be accounted for by variable uptake of phenytoin, which is a substrate of p-glycoprotein, encoded by the human MDR1 gene. We evaluated, whether phenytoin plasma levels correlate with a polymorphism in the MDR1 gene, C3435T, which is associated with intestinal PCP activity. Genotyping and analyses of plasma levels of phenytoin and metabolites in 96 healthy Turkish volunteers showed that the MDR1C > T3435 polymorphism affects phenytoin plasma levels (P = 0.064) and the metabolic ratio of p-HPPH vs phenytoin (MDR1*TT genotype, P = 0.026). The MDR1*CC genotype is more common in volunteers with low phenytoin levels (P ≤ 0.001, χ2 test). A combined analysis of variable alleles of CYP2C9, 2C19 and MDR1 revealed that the number of mutant CYP2C9 alleles is a major determinant, the number of MDR1*T alleles further contributes to the prediction of phenytoin plasma levels and CYP2C19*2 does not explain individual variability. The regression equation that fitted the data best included the number of mutant CYP2C9 and MDR*T alleles as predictory variables and explained 15.4% of the variability of phenytoin data (r2 = 0.154, P = 0.0002). Furthermore, analysis of CYP2C9 and MDR1 genotypes in 35 phenytoin-treated patients recruited from therapeutic drug monitoring showed that combined CYP2C9 and MDR1 analysis has some predictive value not only in the controlled settings of a clinical trial, but also in the daily clinical practice. © 2001 Nature Publishing Group All rights reserved.
引用
收藏
页码:204 / 210
页数:6
相关论文
共 50 条
  • [21] Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population
    Krasniqi, Valon
    Dimovski, Aleksandar
    Bytyqi, Hasime Qorraj
    Eftimov, Aleksandar
    Simicevic, Livija
    Bozina, Nada
    ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, 2017, 68 (03): : 180 - 184
  • [22] Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics
    Kirchheiner, J
    Müller, G
    Meineke, I
    Wernecke, KD
    Roots, I
    Brockmöller, J
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (05) : 459 - 466
  • [23] CYP2C9☆1B Promoter Polymorphisms, in Linkage with CYP2C19☆2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose
    Chaudhry, Amarjit S.
    Urban, Thomas J.
    Lamba, Jatinder K.
    Birnbaum, Angela K.
    Remmel, Rory P.
    Subramanian, Murali
    Strom, Stephen
    You, Joyce H.
    Kasperaviciute, Dalia
    Catarino, Claudia B.
    Radtke, Rodney A.
    Sisodiya, Sanjay M.
    Goldstein, David B.
    Schuetz, Erin G.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 332 (02): : 599 - 611
  • [24] Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene–gene interactions on warfarin therapy
    Koroush Khalighi
    Gang Cheng
    Seyedabbas Mirabbasi
    Bahar Khalighi
    Yin Wu
    Wuqiang Fan
    Journal of Thrombosis and Thrombolysis, 2017, 43 : 124 - 129
  • [25] Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro:: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism
    Shon, JH
    Yoon, YR
    Kim, MJ
    Kim, KA
    Lim, YC
    Liu, KH
    Shin, DH
    Lee, CH
    Cha, IJ
    Shin, JG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 552 - 563
  • [26] Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy
    Song, Cangsang
    Li, Xingde
    Mao, Panpan
    Song, Wenbing
    Liu, Lu
    Zhang, Yang
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (04) : 198 - 201
  • [27] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients
    Kesavan, Ramasamy
    Narayan, Sunil K.
    Adithan, Chandrasekaran
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (07) : 689 - 696
  • [28] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients
    Ramasamy Kesavan
    Sunil K. Narayan
    Chandrasekaran Adithan
    European Journal of Clinical Pharmacology, 2010, 66 : 689 - 696
  • [29] Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene- gene interactions on warfarin therapy
    Khalighi, Koroush
    Cheng, Gang
    Mirabbasi, Seyedabbas
    Khalighi, Bahar
    Wu, Yin
    Fan, Wuqiang
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 43 (01) : 124 - 129
  • [30] CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects
    Yin, OQP
    Tomlinson, B
    Chow, MSS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) : 370 - 377